You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Introduction

Limitations exist in identifying patients with major depressive disorder (MDD) and cognitive impairment, despite a majority of MDD patients exhibiting cognitive symptoms. Cognitive dysfunction also affects patient functional outcomes, including workforce performance and psychosocial interactions. Emerging agents, including multimodal antidepressants, show a promising direct effect on improving cognitive impairment in patients with MDD. Increased knowledge on diagnosis, treatment, long-term management, and integration of emerging treatment options into clinical practice will allow physicians to select appropriate treatment strategies and improve outcomes for patients with MDD and cognitive dysfunction.

Activities

Steering Committee

Steering Committee Chair
  • Guy M. Goodwin, FMedSciGuy M. Goodwin, FMedSci
    Professor of Psychiatry,
    Department of Psychiatry,
    University of Oxford,
    Oxford, United Kingdom
Steering Committee Members
  • John Harrison, CSci, CPsycholJohn Harrison, CSci, CPsychol
    Associate Professor,
    Alzheimer Center,
    VU University Medical Center,
    Amsterdam, The Netherlands
  • Siegfried Kasper, MDSiegfried Kasper, MD
    Professor and Chair,
    Department of Psychiatry
    and Psychotherapy,
    Medical University of Vienna,
    Vienna, Austria
  • Raymond W. Lam, MDRaymond W. Lam, MD, FRCPC
    Professor and Associate
    Head for Research,
    Department of Psychiatry,
    University of British Columbia;
    Director, Mood Disorders Centre,
    UBC Hospital, Vancouver Coastal Health;
    Executive Chair, Canadian Network for
    Mood and Anxiety Treatments (CANMAT),
    Vancouver, British Columbia, Canada
  • Roger S. McIntyre, MD, FRCPCRoger S. McIntyre, MD, FRCPC
    Professor of Psychiatry and
    Pharmacology, University of
    Toronto; Head, Mood Disorders
    Psychopharmacology Unit, University
    Health Network, Toronto,
    Ontario, Canada
  • David J. Nutt, MD, PhDDavid J. Nutt, MD, PhD
    Edmund J. Safra Professor
    of Neuropsychopharmacology;
    Head, Centre for Neuropsychopharmacology,
    Imperial College London,
    London, United Kingdom
Disclaimer: This Clinical Advances is intended for an audience of healthcare professionals located outside the United States.
Supported by an independent educational
grant from
Lundbeck

Related Resources

Downloadable Slide Kit
Clinical Articles

Disclosures

Steering Committee
Guy M. Goodwin, FMedSci

Guy M. Goodwin, FMedSci, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Cephalon, Inc.; GlaxoSmithKline; Janssen-Cilag; Eli Lilly and Company; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Otsuka Pharmaceutical Co., Ltd.; P1vital; Roche; SERVIER; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Neuroscience, Inc.
Received grants for clinical research from: SERVIER
Owns stock, stock options, or bonds from: P1vital
Served as an expert witness for: Eli Lilly and Company

John Harrison, CSci, CPsychol

John Harrison, CSci, CPsychol, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Anavex Life Sciences Corp.; AstraZeneca Pharmaceuticals LP; Avraham Pharmaceuticals; AXON; Biogen Idec Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bracket Global; Catenion; CRF Health; Dendron UK; Eisai Co., Ltd; Eli Lilly and Company; EnVivo Pharmaceuticals; ePharmaSolutions; Heptares; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Kyowa Hakko Kirin Co., Ltd.; Lundbeck, Inc.; MedAvante; Mind Agilis; MyCognition; Neurocog; Novartis Pharmaceuticals Corporation; Nutricia; Orion Corporation; Pfizer Inc; Prana Biotechnology; Pricespective; ProStrakan, Inc.; Reviva Pharmaceuticals Inc; Roche; SERVIER; Shire; TCG; TransTech Pharma; UCB Pharma, Inc.; Velacor
Served as a speaker or a member of a speakers bureau for: Lundbeck, Inc.
Employed by a commercial interest: Metis Cognition Ltd

Siegfried Kasper, MD

Siegfried Kasper, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Angelini; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals Products, L.P.; Eli Lilly and Company; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Organon International Inc.; Pfizer Inc; Pierre Fabre; Schwabe Pharmaceuticals; Sepracor Inc.; SERVIER; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Angelini; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals Products, L.P.; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Organon International Inc.; Pierre Fabre; Schwabe Pharmaceuticals; SERVIER; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Lundbeck, Inc.

Raymond W. Lam, MD, FRCPC

Raymond W. Lam, MD, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Lundbeck, Inc.; Pfizer Inc; Takeda Pharmaceuticals North America, Inc.; The Litebook Company
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Lundbeck, Inc.; Mochida; Pfizer Inc; SERVIER
Received grants for clinical research from: Bristol-Myers Squibb Company; Lundbeck, Inc.; Merck & Co., Inc.; Pfizer Inc; St. Jude Medical; The Litebook Company

Roger S. McIntyre, MD, FRCPC

Roger S. McIntyre, MD, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen-Ortho Inc.; Lundbeck, Inc.; Merck & Co., Inc.; Organon Pharmaceuticals USA Inc.; Pfizer Inc; Shire
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen-Ortho Inc.; Lundbeck, Inc.; Merck & Co., Inc.; Pfizer Inc
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen-Ortho Inc.; Lundbeck, Inc.; Pfizer Inc; Shire

David J. Nutt, MD, PhD

David J. Nutt, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Janssen Pharmaceuticals Products, L.P.; Lundbeck, Inc.
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; GlaxoSmithKline; Eli Lilly and Company; Pfizer Inc; SERVIER
Received grants for clinical research from: GlaxoSmithKline; Lundbeck, Inc.